According to a recent LinkedIn post from Actithera, the company has brought on Hyelim Cho, PhD MBA, as Chief of Staff and Head of Strategy. The post highlights her strategic background in radioligand therapy (RLT), including experience in portfolio direction and decision support across the biopharma sector.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Cho’s expertise in RLT and business development is intended to support refinement of Actithera’s pipeline and long-term planning. For investors, this senior hire may indicate a push to professionalize strategic oversight, potentially accelerating pipeline prioritization, partnering discussions, and value-creation milestones in the competitive radiopharmaceuticals space.